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Comments on the article by Conaghan et al.With interest we read the article written by Conaghan et al.1
The authors concluded that 7-day buprenorphine patches plus
oral paracetamol are non-inferior to co-codamol with respect to
analgesic-efﬁcacy in older people with osteoarthritis pain of the
hip and/or knee. We believe this is a well-conducted study which
attempted to ﬁnd alternatives for pain reduction in older patients
with osteoarthritis, but after reading some questions remained.
First, the authors describe the titration period that patients had
to enter to reach optimal pain control. The authors deﬁne optimal
pain control as sufﬁcient pain control with minimal side effects.
How did the authors decide what minimal side effects are? And
what did the authors deﬁne as sufﬁcient pain control?
Second, a considerable number of patients (103) were lost to
follow-up. The authors report that this high drop-out rate is normal
in opioid trials and that no analyses were performed to look at
differences between the patients who completed and those who
withdrew. Yet, selective dropout could be possible so these analyses
seem mandatory to us.
Third, the authors described their randomization procedure
very well and they clearly stated which inclusion and exclusion
criteria were used. However, we think that the description of the
patients-characteristics is limited. Is it possible to provide data
about body mass index, level of education, osteoarthritis (OA)
(site, duration, and severity), and Western Ontario McMaster Oste-
oarthritis Index (WOMAC) scores? We think these data would be
very important as it may have affected the results. Furthermore,
we wonder whether compliance during the study was recorded.
Fourth, the total study population comprised of 220 patients.
It would be interested to know the number of patients that were
screened, as this may say something about the external validity.
Also, could they explain why the results section described that
the full analysis population included 209 patients, whereas Fig. 1
mentioned 220 patients.DOI of original article: 10.1016/j.joca.2011.12.011.
1063-4584/$ – see front matter  2012 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2011.11.018We would be very interested in the authors’ response to these
comments and questions.
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